Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie, Parkinson's disease and FDA
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be marketed under the trade name Vyalev.
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, offering improved motor control and reduced symptoms. Approval was based on a pivotal Phase 3 study.
AbbVie’s Vyalev approved by FDA in advanced Parkinson’s disease
AbbVie announced that the FDA has approved Vyalev as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.
AbbVie says latest FDA approval expands Botox use beyond face
The U.S. Food and Drug Administration (FDA) has approved the fourth indication for AbbVie's (NYSE:ABBV) anti-wrinkle therapy Botox Cosmetic, expanding its use beyond the face for the first time, the company announced late Friday.
1d
on MSN
Analysts revise AbbVie stock price target ahead of earnings
Related: Analyst revises AbbVie stock price target on drug-sale estimates Sales eroded, however, as Humira faced competition ...
Crain's Chicago Business
2d
New AbbVie Parkinson’s drug finally gets green light to hit U.S. market
After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...
24/7 Wall St
4d
Dividend Aristocrat AbbVie Just Paid Investors; Here's How Much They Received
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.
1d
AbbVie price target raised to $220 from $214 at BMO Capital
BMO Capital raised the firm’s price target on AbbVie to $220 from $214 and keeps an Outperform rating on the shares as part ...
Crain's Chicago Business
5d
AbbVie tries to fast-track new cancer drug for approval to join 2 others in its pipeline
There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...
bovnews
1d
AbbVie Inc (ABBV) Posted 9.63% Profit Margin Last Year—Can It Hold Up?
On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $188.57 which represents a decrease of $-1.89 or -0.99% from the prior close of $190.46. The stock opened at $190.54 and touched a ...
1d
IQ EQ FUND MANAGEMENT IRELAND Ltd Cuts Stock Holdings in AbbVie Inc. (NYSE:ABBV)
IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.0% during the ...
2d
on MSN
Calls of the Day: Crowdstrike, Cheniere Energy, 3M, Abbott Labs, Abbvie and Eli Lilly
The Investment Committee debate the latest Calls Of The Day. How many of the best sci-fi movies ever made have you watched?
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
vyalev
Parkinson's disease
United States
Food and Drug Administration
Calendar year
Feedback